MP201 Drug Synthesis

This Request for Information (RFI)/Sources Sought (SS) Notice is for market research, information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Walter Reed Army Institute of Research (WRAIR) or the US Army Medical Research Acquisition Activity (USAMRAA).  The purpose of this requirement is to provide synthesis of the prodrug of 2,4-dinitrophenol (DNP) called MP201, against ocular dysfunction caused by blast exposure. The Contractor shall support WRAIR’s Blast Induced Neurotrauma Branch’s (BINT) study on the efficacy of MP201 by data interpretation/analysis, preparation of quarterly reports, annual progress reports, manuscripts, and final project report.  This announcement is not a formal solicitation and is not a request for proposal.  No contract will be awarded from this announcement.  No reimbursement will be made of any costs to provide information in response to this announcement or any follow up information requests.  Availability of any formal solicitation will be announced under a separate announcement.  This synopsis is for market research, information and planning purposes only and is not to be construed as a commitment by the Government. Each response must reference the sources sought title. All proprietary information should be marked as such. Responses will be held confidential if requested.

RFI Response and due date: 13 June 2024 12:00PM ET

Instructions to Responders:

Responses from all capable and qualified sources are encouraged to respond to this request. 

White papers should adhere to the following formatting and outline instructions:

1.   All submissions shall be made electronically and be in one of the following formats: Microsoft Word or Adobe PDF.

2. Cover Page (1page)

• Title
• Organization
• Responders technical and administrative points of contact (names, addresses, phone, fax number and email addresses)
• Topic area(s) addressed

3.   Please note that the response shall provide sufficient technical data to determine how you fully meet the requirements as specified.  

Please note that responses are due no later than 13 June 2024 12:00PM ET.  The preferred method of submission is via email, with the subject line: “MP201 Drug Synthesis.”  The point of contact for this action is Ms. Dawn Jennings, Contract Specialist dawn.v.jennings.civ@health.mil .  Only electronic responses are requested.  No evaluation letters and/or results will be issued to the respondents.  At this time no solicitation exists; therefore, please do not request a copy of the solicitation.